CompletedPHASE1, PHASE2NCT02124083
Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1
Studying Infantile neurovisceral acid sphingomyelinase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Principal Investigator
- Forbes D Porter, M.D.Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Intervention
- Vorinostat(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2014 – 2016
Study locations (1)
- National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Collaborators
Washington University School of Medicine · Weill Medical College of Cornell University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02124083 on ClinicalTrials.gov